Conferences
ASCO GU 2024: Real-world Comparison of PSA Response in Patients with mCSPC Treated with Apalutamide or Enzalutamide
January 28, 2024
ASCO GU 2024: 3TMPO: Prognostic Value of FDG, PSMA, and DOTATATE Uptake on PET Imaging in mCRPC
January 28, 2024
ASCO GU 2024: ProstAct-SELECT: Safety, Tolerability, and Dosimetry of 177Lu-TLX591 with Best Standard of Care in Patients with PSMA-Expressing mCRPC
January 28, 2024
ASCO GU 2024: Real-world Treatment Sequences and Time to Discontinuation in the First-line mCRPC Setting
January 28, 2024
ASCO GU 2024: Population Based Trends in Intravesical Gemcitabine Use Among Patients with High-Risk Non-Muscle Invasive Bladder Cancer
January 28, 2024
ASCO GU 2024: Insights from CheckMate 67T and Patient-Reported Outcomes in LITESPARK-005 for Advanced RCC
January 28, 2024
ASCO GU 2024: The Role of Radiation in Primary Tumor and Distant Sites in Managing Renal Cell Carcinoma
January 28, 2024
ASCO GU 2024: Phase III Randomized Trial of Stereotactic Ablative Radiotherapy for Oligometastatic Advanced Renal Carcinoma (EA8211-SOAR)
January 28, 2024